InvestorsHub Logo
Followers 2
Posts 436
Boards Moderated 0
Alias Born 01/14/2014

Re: None

Thursday, 12/19/2019 8:59:31 AM

Thursday, December 19, 2019 8:59:31 AM

Post# of 807
Oxford Biomedica PLC
19 December 2019
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Oxford Biomedica Extends Commercial Supply Agreement by Five Years for Manufacture of Lentiviral Vectors
Oxford, UK - 19 December 2019: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, announced today that it has extended its commercial supply agreement with Novartis for the manufacture of lentiviral vectors for the Novartis CAR-T portfolio including five lentiviral vectors for CAR-T products. This builds on the existing three year commercial supply agreement signed by the parties in July 2017.
Under the terms of the Agreement, Oxford Biomedica will receive a minimum $75 million from Novartis over the next five years in manufacturing revenue with additional undisclosed process development fees. A mid single digit GBPm payment will also be paid in the medium term as a facility reservation fee with other terms such as royalties on net sales of resulting CAR-T products as previously agreed in 2014.
Oxford Biomedica will dedicate a manufacturing facility to Novartis within its new 7,800m(2) commercial manufacturing centre OxBox, in Oxford, UK. Oxford Biomedica will also be responsible for ensuring that at least two of its GMP facilities are capable of commercial supply for Novartis' CAR-T progammes.
John Dawson, Chief Executive Officer of Oxford Biomedica, said: "This five year extension to our commercial supply agreement with Novartis for the LentiVector(R) platform is testament to the joint success achieved in this strategically important collaboration since 2013. This closely integrated collaboration with Novartis underlines the long-term committment both companies have made to manufacturing CAR-T therapies.
"This is also the first long-term commitment of a partner to reserve a dedicated GMP facility in our new OxBox GMP facility, which we expect to become operational in early 2020. While stable and long-term supply of lentiviral vectors for commercial CAR-T products is key to both companies, we are also pleased to announce that we are now working on five different lentiviral vectors for CAR-T products in the Novartis portfolio and we look forward to helping Novartis to innovate in this exciting therapeutic space".